Your shopping cart is currently empty

EGFR-IN-187 (Compound 4d) is a selective EGFR inhibitor with an IC50 of 25.41 μM. It exhibits inhibitory activity against PANC-1 and A549 cells with IC50 values of 0.067 μM and 2.29 μM, and selectivity indices (SI) of 1521 and 21, respectively. EGFR-IN-187 causes cancer cells to arrest in the S and G2/M phases and induces apoptosis and autophagy. It upregulates the expression of CCNE1, Bax, LC3B-II, and P27, while downregulating CCNA1 and Bcl-2 levels. EGFR-IN-187 is applicable for cancer research, including studies on lung cancer.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | EGFR-IN-187 (Compound 4d) is a selective EGFR inhibitor with an IC50 of 25.41 μM. It exhibits inhibitory activity against PANC-1 and A549 cells with IC50 values of 0.067 μM and 2.29 μM, and selectivity indices (SI) of 1521 and 21, respectively. EGFR-IN-187 causes cancer cells to arrest in the S and G2/M phases and induces apoptosis and autophagy. It upregulates the expression of CCNE1, Bax, LC3B-II, and P27, while downregulating CCNA1 and Bcl-2 levels. EGFR-IN-187 is applicable for cancer research, including studies on lung cancer. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.